Immune-Boosting drug tested to stop aggressive lymphoma from coming back
NCT ID NCT02362997
Summary
This study tested whether adding the immunotherapy drug pembrolizumab after a patient's own stem cell transplant could help keep certain aggressive lymphomas from returning. It involved 82 adults with Hodgkin lymphoma, diffuse large B-cell lymphoma, or T-cell lymphoma that had come back or didn't respond to initial treatment. The main goal was to see if this extra treatment helped more patients stay cancer-free for at least 18 months after their transplant.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for DIFFUSE LARGE B-CELL LYMPHOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Beth Israel Deaconess Medical Center
Boston, Massachusetts, 02215, United States
-
City of Hope National Medical Center
Duarte, California, 91010, United States
-
Dana Farber Cancer Institute
Boston, Massachusetts, 02215, United States
-
MD Anderson Cancer Center
Houston, Texas, 77030, United States
-
Massachusetts General Hospital
Boston, Massachusetts, 02114, United States
-
Memorial Sloan Kettering Cancer Center
New York, New York, 10065, United States
Conditions
Explore the condition pages connected to this study.